BRPI0410876B8 - composição, proteína de fusão, molécula de cdna, vetor, célula hospedeira procariótica recombinante, método para preparar uma molécula inibidora do complemento, e, usos de uma composição e de uma proteína de fusão - Google Patents

composição, proteína de fusão, molécula de cdna, vetor, célula hospedeira procariótica recombinante, método para preparar uma molécula inibidora do complemento, e, usos de uma composição e de uma proteína de fusão

Info

Publication number
BRPI0410876B8
BRPI0410876B8 BRPI0410876A BRPI0410876A BRPI0410876B8 BR PI0410876 B8 BRPI0410876 B8 BR PI0410876B8 BR PI0410876 A BRPI0410876 A BR PI0410876A BR PI0410876 A BRPI0410876 A BR PI0410876A BR PI0410876 B8 BRPI0410876 B8 BR PI0410876B8
Authority
BR
Brazil
Prior art keywords
composition
fusion protein
molecule
vector
making
Prior art date
Application number
BRPI0410876A
Other languages
English (en)
Inventor
Andrew Nunn Miles
Original Assignee
Evolutec Ltd
Varleigh Ltd
Varleigh Immuno Pharm Vip Ltd
Volution Immuno Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312619A external-priority patent/GB0312619D0/en
Priority claimed from GB0327386A external-priority patent/GB0327386D0/en
Application filed by Evolutec Ltd, Varleigh Ltd, Varleigh Immuno Pharm Vip Ltd, Volution Immuno Pharmaceuticals Sa filed Critical Evolutec Ltd
Publication of BRPI0410876A publication Critical patent/BRPI0410876A/pt
Publication of BRPI0410876B1 publication Critical patent/BRPI0410876B1/pt
Publication of BRPI0410876B8 publication Critical patent/BRPI0410876B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43552—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects
    • G01N2333/43556—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects from ticks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/42—Poisoning, e.g. from bites or stings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Diabetes (AREA)

Abstract

molécula inibidora do complemento, anticorpo, proteína de fusão, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar uma molécula inibidora do complemento ou um seu equivalente funcional ou uma proteína de fusão, para identificar um ligando de uma molécula inibidora do complemento, ou um seu equivalente funcional, para tratar um animal que esteja sofrendo de uma doença ou um distúrbio mediados pelo complemento, ou prevenir que um animal desenvolva uma doença ou um distúrbio mediados pelo complemento, para vacinar um animal contra uma doença ou um distúrbio transmitidos por um artrópode hematófago e para inibir as vias do complemento clássica e alternativa em uma célula, tecido ou organismo não humano, composição, uso de uma molécula inibidora do complemento, uma proteína de fusão ou uma molécula de ácido nucleico a invenção diz respeito a inibidores do complemento, que inibem tanto a via clássica quanto a alternativa do complemento. em particular, a invenção diz respeito a inibidores do complemento derivados das glândulas salivares de artrópodes hematófagos que inibem tanto a via clássica quanto a alternativa do complemento. a invenção também diz respeito ao uso de tais inibidores do complemento no tratamento e prevenção de doenças.
BRPI0410876A 2003-06-02 2004-06-02 composição, proteína de fusão, molécula de cdna, vetor, célula hospedeira procariótica recombinante, método para preparar uma molécula inibidora do complemento, e, usos de uma composição e de uma proteína de fusão BRPI0410876B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0312619.0 2003-06-02
GB0312619A GB0312619D0 (en) 2003-06-02 2003-06-02 Complement inhibitors
GB0327386A GB0327386D0 (en) 2003-11-25 2003-11-25 Complement inhibitors
GB0327386.9 2003-11-25
PCT/GB2004/002341 WO2004106369A2 (en) 2003-06-02 2004-06-02 Complement inhibitors from ticks

Publications (3)

Publication Number Publication Date
BRPI0410876A BRPI0410876A (pt) 2006-07-04
BRPI0410876B1 BRPI0410876B1 (pt) 2020-11-03
BRPI0410876B8 true BRPI0410876B8 (pt) 2023-01-24

Family

ID=33492257

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410876A BRPI0410876B8 (pt) 2003-06-02 2004-06-02 composição, proteína de fusão, molécula de cdna, vetor, célula hospedeira procariótica recombinante, método para preparar uma molécula inibidora do complemento, e, usos de uma composição e de uma proteína de fusão

Country Status (13)

Country Link
US (5) US7884188B2 (pt)
EP (1) EP1629098B1 (pt)
JP (1) JP4772667B2 (pt)
AT (1) ATE427356T1 (pt)
AU (1) AU2004242759B2 (pt)
BR (1) BRPI0410876B8 (pt)
CA (1) CA2526083C (pt)
DE (1) DE602004020334D1 (pt)
ES (1) ES2324993T3 (pt)
HK (1) HK1085511A1 (pt)
MX (1) MXPA05012880A (pt)
NZ (1) NZ544163A (pt)
WO (1) WO2004106369A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012880A (es) * 2003-06-02 2006-02-22 Evolutec Ltd Inhibidores de complemento.
PT1713503E (pt) 2004-02-10 2013-11-14 Nat Jewish Health Inibição do factor b, a via alternativa do complemento e métodos relacionados
KR20130100207A (ko) 2005-02-14 2013-09-09 유니버시티 오브 아이오와 리써치 파운데이션 연령­관련 황반 변성의 치료 및 진단용 방법 및 시약
CN101227924A (zh) 2005-05-26 2008-07-23 科罗拉多大学评议会 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
BRPI0619747B8 (pt) 2005-12-12 2021-05-25 Ac Immune Sa método para produzir uma composição de vacina terapêutica, construto antigênico, composição de vacina, usos de um construto antigênico, e, método para preparar e produzir um medicamento para o tratamento de uma condição ou doença associada com amilóide
JP2010502687A (ja) * 2006-09-08 2010-01-28 ヴァーレイ・リミテッド 呼吸器疾患の治療方法
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
PL2148691T3 (pl) * 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
CN101668773B (zh) 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
US20090324585A1 (en) * 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
CN101928709B (zh) * 2009-06-24 2012-05-23 中国农业科学院上海兽医研究所 一种亚洲璃眼蜱的组胺结合蛋白HaHBP的基因序列和重组表达与应用
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
JP5840623B2 (ja) * 2010-01-08 2016-01-06 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 気道のウイルス感染症の治療に用いるｅｖ５７６
US20130058931A1 (en) 2010-03-11 2013-03-07 University Of Louisville Research Foundation, Inc. Methods of predicting and decreasing the risk of pregnancy loss
WO2012078968A2 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
US8961981B2 (en) 2011-06-20 2015-02-24 Saint Louis University Targeting the neuromuscular junction for treatment
CA2840270C (en) 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US9808502B2 (en) 2012-02-20 2017-11-07 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement C5
EP2855529A4 (en) 2012-05-24 2015-12-09 Alexion Pharma Inc HUMANIZED ANTI-FACTOR B ANTIBODIES
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2017210537A1 (en) 2016-06-02 2017-12-07 The Cleveland Clinic Foundation Complement inhibition for improving cell viability
JP7102353B2 (ja) 2016-06-14 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｃ５抗体及びそれらの使用
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2018193122A1 (en) 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of autoimmune blistering diseases
SG11202004662RA (en) 2017-12-13 2020-06-29 Regeneron Pharma Anti-c5 antibody combinations and uses thereof
WO2020053206A1 (en) 2018-09-10 2020-03-19 Volution Immuno Pharmaceuticals Sa Coversin for use in the treatment of rheumatic diseases
GB201905810D0 (en) 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
CA3153803A1 (en) 2019-09-27 2021-04-01 Volution Immuno Pharmaceuticals Sa Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (hsct-tma)
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3734093A (en) 1992-02-27 1993-09-13 Merck & Co., Inc. Protein for inhibiting collagen-stimulated platelet aggregation
US7884066B2 (en) * 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
MXPA05012880A (es) * 2003-06-02 2006-02-22 Evolutec Ltd Inhibidores de complemento.

Also Published As

Publication number Publication date
JP4772667B2 (ja) 2011-09-14
WO2004106369A3 (en) 2005-02-17
BRPI0410876B1 (pt) 2020-11-03
US20160096870A1 (en) 2016-04-07
JP2007536894A (ja) 2007-12-20
US20070141573A1 (en) 2007-06-21
AU2004242759A1 (en) 2004-12-09
DE602004020334D1 (de) 2009-05-14
ATE427356T1 (de) 2009-04-15
NZ544163A (en) 2009-06-26
MXPA05012880A (es) 2006-02-22
ES2324993T3 (es) 2009-08-21
EP1629098A2 (en) 2006-03-01
US7884188B2 (en) 2011-02-08
US8993264B2 (en) 2015-03-31
US9834585B2 (en) 2017-12-05
BRPI0410876A (pt) 2006-07-04
US20110263482A1 (en) 2011-10-27
AU2004242759B2 (en) 2009-11-26
WO2004106369A2 (en) 2004-12-09
US20180127472A1 (en) 2018-05-10
CA2526083A1 (en) 2004-12-09
HK1085511A1 (en) 2006-08-25
US20220363726A1 (en) 2022-11-17
CA2526083C (en) 2017-01-17
EP1629098B1 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
BRPI0410876B8 (pt) composição, proteína de fusão, molécula de cdna, vetor, célula hospedeira procariótica recombinante, método para preparar uma molécula inibidora do complemento, e, usos de uma composição e de uma proteína de fusão
DE602005020611D1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
EA200501805A1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
MX2007004841A (es) Triazoles utiles como inhibidores de proteinas cinasas.
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO20062315L (no) Minimal DNA-sekvens som virker som en kromatinisolator og dets anvendelse i proteinekspresjon
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
DK1420801T3 (da) Anvendelse af fucaner til behandling af adhæsioner, arthritis og psoreasis
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
EA201100072A1 (ru) Новые композиции и способы
NZ593815A (en) Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
BRPI0416268A (pt) composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
EA201100071A1 (ru) Новые композиции и способы
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
NO20055210D0 (no) Inhibitorproteiner av en protease og anvendelse derav
AR106538A1 (es) Métodos y composiciones para el tratamiento de la amiloidosis
BRPI0515893B8 (pt) peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: EVOLUTEC LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: VARLEIGH LIMITED (GB)

B25D Requested change of name of applicant approved

Owner name: VARLEIGH IMMUNO PHARMACEUTICALS (VIP) LIMITED (VG)

B25G Requested change of headquarter approved

Owner name: VARLEIGH IMMUNO PHARMACEUTICALS (VIP) LIMITED (VG)

B25A Requested transfer of rights approved

Owner name: VOLUTION IMMUNO PHARMACEUTICALS SA (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/06/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2600, DE 03/11/2020. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 03/11/2020, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS?